C86.5
Angioimmunoblastic T-cell lymphoma
Clinical Classification Guidelines
Inclusion Terms
- Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)
Medical Intelligence & Overview
Angioimmunoblastic T-cell lymphoma (AITL) is a rare type of lymphoma, which is a cancer that begins in the lymphatic system. Specifically, AITL arises from T-cells, a type of white blood cell that plays a vital role in the immune system. This condition is considered an aggressive form of non-Hodgkin lymphoma and is characterized by abnormal growth within lymph nodes and other lymphoid tissues. It often presents with widespread disease involving multiple lymph nodes and sometimes other organs. Historically, it was associated with a condition called angioimmunoblastic lymphadenopathy with dysproteinemia (AILD), which features immune system abnormalities and abnormal protein levels in the blood.
Causes & Symptoms
Clinical Causes: The exact cause of AITL is unknown, but it involves genetic mutations within T-cells that lead to uncontrolled growth. Potential genetic predispositions may increase susceptibility, although no specific inherited factors have been identified. The disease is not contagious and does not result from environmental exposures like chemicals or radiation. Alterations in immune system regulation and infections, such as Epstein-Barr virus (EBV), have been associated with some cases. Older age and immune deficiencies can increase risk, but these are not direct causes of AITL.
Key Symptoms: Swollen lymph nodes, often in the neck, armpits, or groin Fever and chills that persist over time Unintentional weight loss Profuse sweating, especially at night Fatigue and weakness Skin rashes or skin changes Difficulty breathing if lymph nodes in the chest swell Abdominal discomfort or swelling from enlarged organs Itching or skin irritation Signs of immune system malfunction, such as frequent infections
Diagnostic & Treatment
Diagnosis Path: Diagnosing AITL involves a combination of medical history review, physical examination, and laboratory tests. A key step is a biopsy of affected lymph nodes or other involved tissues, which allows pathologists to examine cell types and identify characteristic features of AITL. Additional tests may include:
Treatment Protocols: Management of AITL generally involves therapies aimed at controlling disease progression and alleviating symptoms. Treatment options may include:
Clinical Advice & FAQs
Billing Guidance
Is C86.5 a billable ICD-10 code?
Yes, C86.5 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C86.5?
Clinical documentation must specify the nature of Angioimmunoblastic T-cell lymphoma and any associated comorbidities for accurate reporting.
Cite this Clinical Reference